Skip to main content
Top
Published in: Breast Cancer Research 1/2000

01-03-2000 | Meeting abstract

Expression of variant forms of the MUC1 gene correlates with the invasiveness of breast cancer cells

Authors: R Zeillinger, B Schmid, D Tong, B Fasching, I Schiebl, M Stimpfl, A Obermair, S Leodolter

Published in: Breast Cancer Research | Special Issue 1/2000

Login to get access

Excerpt

The characterization of tumor markers is of prime importance in understanding the mechanisms underlying cancer initiation and progression. The most exclusively used marker for monitoring breast cancer patients are the protein products of the MUC1 gene, which is strongly overexpressed in breast cancer cells. The best characterized MUC1 gene product is MUC1/REP (episialin, PEM, CA15-3, MCA). It is important in reducing cell-cell and cell-extracellular matrix interactions, probably being involved in the spread of cancer cells from the primary tumor. MUC1 overexpression was found to correlate with invasiveness. Four isoforms are generated by differential splicing due to the use of alternative splice acceptor sites for exon 1. These were designated variants A to D. A higher expression of variant A than of variant B was found to indicate thyroid papillary carcinomas. …
Metadata
Title
Expression of variant forms of the MUC1 gene correlates with the invasiveness of breast cancer cells
Authors
R Zeillinger
B Schmid
D Tong
B Fasching
I Schiebl
M Stimpfl
A Obermair
S Leodolter
Publication date
01-03-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr117

Other articles of this Special Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine